Travere Therapeutics (TVTX) Is Up 6.1% After FILSPARI Beats FSGS Launch Expectations
Travere Therapeutics (TVTX) saw its stock rise by 6.1% following news that its drug FILSPARI's launch for FSGS is exceeding expectations, driven by strong physician demand. This success reinforces the company's kidney-focused portfolio, which also includes a Phase III trial for pegtibatinase and the addition of civorebrutinib to its pipeline. While the strong launch boosts near-term growth, the article also notes the ongoing risk of heavy reliance on FILSPARI and increasing competition in the kidney disease market.
Travere Therapeutics (TVTX) director sells 10K shares under 10b5-1 plan
Travere Therapeutics (TVTX) director Gary A. Lyons exercised options for 10,000 shares and subsequently sold all 10,000 shares of common stock between August 17-18, 2026. The sales were conducted under a pre-arranged 10b5-1 trading plan adopted on May 18, 2026. Lyons acquired the shares at an exercise price of $17.44 per share and sold them in multiple tranches at weighted-average prices ranging from approximately $62.53 to $64.16 per share.
US High Growth Tech Stocks To Watch In August 2026
This article identifies top US high-growth tech stocks for August 2026, noting a flat market over the last week but a 19% rise over the past year. It highlights companies like Travere Therapeutics, AnaptysBio, and Coherent, detailing their growth ratings, revenue, earnings projections, and strategic developments. The analysis focuses on companies with robust growth potential and innovative approaches in their respective fields.
Travere Therapeutics (NASDAQ: TVTX) director plans 5,000-share sale tied to stock options
Travere Therapeutics director Gary Lyons plans to sell 5,000 shares of company common stock for an aggregate market value of $317,650.00, linked to the exercise of stock options. This sale, scheduled for August 18, 2026, follows a previous 10b5-1 sale of 5,000 shares on August 17, 2026, which generated $315,985.50. The transaction is being handled by Morgan Stanley Smith Barney.
US High Growth Tech Stocks To Watch In August 2026
This article identifies top US high-growth tech stocks for August 2026, noting the market's stability and expected earnings growth. It highlights companies like Travere Therapeutics, AnaptysBio, and Coherent, detailing their financial performance, growth potential, and strategic focus within their respective sectors, despite some currently being unprofitable. The analysis emphasizes innovative therapies and advanced technologies as key drivers for future profitability and market outperformance.
Travere Therapeutics Sees FILSPARI FSGS Launch Top Expectations, Expands Renal Pipeline
Travere Therapeutics (NASDAQ:TVTX) is experiencing a stronger-than-expected launch for FILSPARI in FSGS, with broad physician demand and significant market potential. The company's IgA nephropathy business also continues to grow, contributing to a projected peak sales opportunity exceeding $3 billion. Additionally, Travere is advancing pegtibatinase in a Phase III trial for classical homocystinuria and expanding its renal pipeline with civorebrutinib, a new BTK inhibitor targeting primary membranous nephropathy, immune-mediated FSGS, and minimal change disease.
Travere Therapeutics, Inc. SEC Filing (Aug 17, 2026)
This article details a Form 144 SEC filing by Travere Therapeutics, Inc. (TVTX) on August 17, 2026. The filing indicates a proposed sale of 5,000 shares of common stock by an unnamed individual, acquired through the exercise of stock options on the same date, with an aggregate market value of $310,700.00. The transaction was handled by Morgan Stanley Smith Barney LLC and is expected to occur on NASDAQ.
S&CO Inc. Makes New Investment in Travere Therapeutics, Inc. $TVTX
S&CO Inc. has acquired a new stake of 56,000 shares in Travere Therapeutics, Inc. (NASDAQ:TVTX), valued at approximately $3.18 million. This investment comes as several other institutional investors have also adjusted their holdings in the company. Travere Therapeutics shares opened at $62.14, reflecting positive market sentiment and favorable analyst ratings, with an average price target of $61.67.
Travere Therapeutics (TVTX) Is Up 7.5% After Strong Q2 Revenue But Wider Net Loss - Has The Bull Case Changed?
Travere Therapeutics reported strong Q2 2026 revenue of US$169.58 million, a significant increase from the previous year, but also a wider net loss of US$34.8 million. The article discusses how this revenue growth, driven by its drug FILSPARI, reinforces the company's investment narrative focused on rare kidney diseases, despite ongoing losses from high R&D and commercial spending. Investors are urged to consider the balance between market traction and increasing costs, with analyst forecasts suggesting potential upside but also significant risks.
Travere Therapeutics (TVTX) sees Armistice Capital report 1.67% ownership in 13G/A
Armistice Capital and Steven Boyd have filed an amended Schedule 13G disclosing a 1.67% beneficial ownership stake in Travere Therapeutics (TVTX). This ownership translates to 1,572,539 shares of common stock, with shared voting and dispositive power, falling below the 5% reporting threshold for a passive investment. The shares are directly held by Armistice Capital Master Fund Ltd., with Armistice Capital acting as the investment manager.
Bank of America Corp DE Trims Position in Travere Therapeutics, Inc. $TVTX
Bank of America Corp DE has reduced its stake in Travere Therapeutics, Inc. (NASDAQ:TVTX) by 27.8% in the first quarter, selling over 500,000 shares while still retaining a significant holding. Despite this divestment, several other major institutional investors increased their positions in the biopharmaceutical company. Analyst sentiment remains largely positive, with a "Moderate Buy" consensus and an average price target of $61.67.
Travere Therapeutics (TVTX) Is Up 7.5% After Strong Q2 Revenue But Wider Net Loss - Has The Bull Case Changed?
Travere Therapeutics (TVTX) reported strong Q2 2026 revenue of US$169.58 million, up from US$114.45 million the previous year, but also a wider net loss of US$34.8 million. The company's investment narrative remains focused on the commercial traction of its rare kidney disease treatments, particularly FILSPARI, despite increased spending on R&D and commercialization. Analyst forecasts for 2029 project significant revenue and earnings growth, though some estimates are more conservative due to rising costs and competition.
Travere Therapeutics, Inc. Stock 12‑Month Price Target Raised to $74.62, Implies 20% Upside
Travere Therapeutics, Inc. (TVTX) has seen its average 12-month price target increased by analysts from $72.79 to $74.62, suggesting a 20% potential upside from its Aug. 12 closing price. The consensus rating for the stock remains a "Buy," with 13 out of 14 analysts recommending it.
Travere Therapeutics (TVTX) Is Up 7.5% After Strong Q2 Revenue But Wider Net Loss - Has The Bull Case Changed?
Travere Therapeutics (TVTX) reported strong Q2 2026 revenue of US$169.58 million, up from US$114.45 million year-over-year, but also a wider net loss of US$34.8 million. The company's investment narrative remains focused on FILSPARI uptake and its rare kidney disease portfolio driving future profitability, despite ongoing high R&D and commercial expenses. While revenue growth is positive, the increased losses highlight the significant investment required, suggesting the core risk balance for investors has not fundamentally changed.
Bank of America Corp (TVTX) discloses 5.8% beneficial stake in Travere Therapeutics
Bank of America Corporation has disclosed a 5.8% beneficial ownership stake in Travere Therapeutics, Inc., amounting to 5,439,155 shares. This filing, a Schedule 13G, indicates that Bank of America and its subsidiaries hold shared voting power over 5,103,492 shares and shared dispositive power over 5,325,237 shares, with no sole voting or dispositive power. The ownership percentage is based on Travere's 94,174,767 shares outstanding as of June 30, 2026.
Travere Therapeutics, Inc. $TVTX Shares Bought by Quantinno Capital Management LP
Quantinno Capital Management LP significantly increased its holdings in Travere Therapeutics (NASDAQ:TVTX) by 354.4% in the first quarter, now owning 68,317 shares valued at $2.03 million. Other institutional investors also boosted their stakes, and several analysts have raised their price targets for the stock, resulting in a consensus "Moderate Buy" rating. Insider activity saw two directors sell shares through pre-arranged plans, while the company's lead product, sparsentan, continues to drive its focus on rare kidney and genetic disorders.
State Street Corporation (TVTX) discloses 4.6% beneficial stake in Travere
State Street Corporation reported a 4.6% beneficial ownership stake in Travere Therapeutics, Inc. common stock, totaling 4,256,224 shares as of June 30, 2026. This Schedule 13G filing indicates that State Street, through its investment management subsidiaries, holds these shares with shared voting and dispositive power but no sole control. The report confirms that the ownership is below the 5% threshold, signifying a passive investment.
Travere Therapeutics, Inc. 2026 Q2 - Results - Earnings Call Presentation (NASDAQ:TVTX) 2026-08-06
This article provides the slide deck published by Travere Therapeutics, Inc. for their 2026 Q2 earnings call. The company reported an EPS of -$0.10, missing estimates by $0.42, but revenue of $169.58M, beating by $12.32M and showing a 48.17% year-over-year increase. The earnings call presentation offers further details on these results.
FMR LLC (TVTX) discloses 7.1M Travere Therapeutics shares under amended 13G
FMR LLC and Abigail P. Johnson have filed an amended Schedule 13G, disclosing their beneficial ownership of 7,142,482.22 shares of Travere Therapeutics Inc. (TVTX) common stock, which represents a 7.7% stake. FMR LLC holds sole voting power over 6,173,667.45 shares and sole dispositive power over all 7,142,482.22 shares. Abigail P. Johnson has sole dispositive power over the same number of shares but no voting power.
TRAVERE THERAPEUTICS, INC. : LEERINK PARTNERS RAISES TARGET PRICE TO $78 FROM $55
LEERINK PARTNERS has increased its target price for TRAVERE THERAPEUTICS, INC. (TVTX.O) from $55 to $78. This update was reported by Reuters on August 5, 2026. The article reiterates that this content reflects the author's opinion and is not investment advice.
Travere Therapeutics, Inc. Stock 12‑Month Price Target Raised to $68.36, Implies 22% Upside
Analysts have raised the average 12-month price target for Travere Therapeutics, Inc. (TVTX) stock from $59.14 to $68.36, indicating a potential 22% upside from its Aug. 4 closing price. The consensus rating remains "Buy" among 15 analysts, with forecasts ranging from $49 to $80 per share.
Travere Therapeutics Reports Second Quarter 2026 Financial Results
Travere Therapeutics (Nasdaq: TVTX) reported strong second-quarter 2026 financial results, driven by robust demand for FILSPARI, with U.S. net product sales growing 96% year-over-year to $141 million. The company announced the successful launch of FILSPARI in FSGS and continued growth in IgA nephropathy, alongside advancing its pegtibatinase program into Phase 3 for classical HCU. Travere also expanded its pipeline by in-licensing civorebrutinib for multiple immune-mediated rare kidney diseases, signaling new opportunities for long-term growth.
Travere Therapeutics, Inc. Stock 12‑Month Price Target Raised to $65.71, Implies 17% Upside
Analysts have raised the average 12-month price target for Travere Therapeutics, Inc. (TVTX) stock to $68.36, up from $59.14. This new target suggests a potential upside of approximately 22% from the August 4th closing price. The consensus rating from 15 analysts remains a "Buy," with 14 recommending a Buy and 1 a Hold.
Travere Therapeutics Inc (TVTX) (Q2 2026) Earnings Call Highlights: Record FILSPARI Demand and ...
Travere Therapeutics reported strong Q2 2026 results, driven by record demand for FILSPARI, particularly with its successful launch in FSGS, exceeding initial expectations. The company also strengthened its balance sheet and expanded its rare kidney disease portfolio through a new licensing agreement, despite facing ongoing challenges like payer pushback and higher gross-to-net discounts.
TRAVERE THERAPEUTICS, INC. : JEFFERIES RAISES TARGET PRICE TO $64 FROM $54
Jefferies has raised its target price for Travere Therapeutics, Inc. (TVTX.O) to $64 from the previous $54. This indicates a more optimistic outlook by the firm on the pharmaceutical company's future performance. The report was published by Reuters on August 5, 2026.
Earnings call transcript: Travere Therapeutics jumps on q2 2026 sales beat
Travere Therapeutics reported Q2 2026 revenue of $169.6 million, exceeding analyst forecasts, driven by strong sales of its kidney drug FILSPARI. The drug's sales rose 96% year-over-year to $141.1 million, benefiting from accelerated demand in both IgA nephropathy and the newly launched FSGS indication. Shares surged over 12% in after-hours trading following the positive financial results and optimistic management commentary.
Travere Therapeutics Q2 Swings to Adjusted Loss, Revenue Rises
Travere Therapeutics reported an adjusted loss in Q2 compared to a profit last year, despite an increase in revenue. The company's adjusted net loss was $0.34 per share, while total revenue grew to $65.4 million from $51.7 million in the prior year quarter. The full-year 2024 total revenue guidance was reiterated at $290 million to $310 million.
Earnings Flash (TVTX) Travere Therapeutics, Inc. Reports Q2 Revenue $169.6M, vs. FactSet Est of $157.3M
Travere Therapeutics, Inc. (TVTX) announced its Q2 revenue of $169.6 million, exceeding FactSet's estimate of $157.3 million. This financial update indicates a stronger-than-anticipated performance for the biopharmaceutical company during the second quarter of 2026. The company specializes in therapies for rare kidney and metabolic diseases, with its product FILSPARI (sparsentan) being a key focus.
Liquidity Mapping Around (TVTX) Price Events
This article analyzes Travere Therapeutics Inc. (NASDAQ: TVTX) focusing on liquidity mapping and price events. It highlights weak near-term sentiment challenging long-term strength, an exceptional risk-reward short setup, and divergent sentiment across different time horizons. The report also provides three distinct AI-generated trading strategies (Position, Momentum Breakout, and Risk Hedging) tailored for various risk profiles and holding periods, along with multi-timeframe signal analysis.
Travere Therapeutics Market Sentiment
This article analyzes market sentiment for Travere Therapeutics (TVTX) by examining analyst consensus, short interest, options flow, and insider activity. Analysts show a "Buy" consensus with an average price target of $44, while short interest is declining, and options flow indicates bullish sentiment with more calls than puts. The article also provides a detailed list of recent analyst actions and price target changes.
Travere Therapeutics Number of Employees 2026 | Employee Count & Headcount Data
Travere Therapeutics (NASDAQ: TVTX) had 496 employees worldwide as of March 2026, marking a 4.6% growth since 2023. The company is actively hiring, although job postings have declined by 90.2% in 2026. The average employee salary is $211,323, and overall employee sentiment is negative and declining.
Travere Therapeutics faces earnings test on Filspari FSGS launch By Investing.com
Travere Therapeutics Inc. is approaching its second-quarter earnings report, where investors will closely monitor the performance of its newly FDA-approved kidney drug, Filspari, for focal segmental glomerulosclerosis (FSGS). Analysts anticipate a loss of 8 cents per share on revenue of $160.7 million, with a bullish "buy" rating from most analysts. The report is expected to shed light on Filspari's uptake in the new FSGS market and its continued momentum in IgA nephropathy, alongside overall profitability.
Press Release: Travere Therapeutics to Report Second Quarter 2026 Financial Results
Travere Therapeutics announced it will report its second quarter 2026 financial results on July 30, 2026. The company will also host a conference call and webcast to discuss these results and provide a business update.
TVTX|Travere Therapeutics Inc|Price:55.890|Chg%:-0.790
Travere Therapeutics Inc (TVTX) shows relatively stable fundamentals and high growth potential, though its valuation is considered fairly valued within the Biotechnology & Medical Research industry. Analysts predominantly rate the stock as "Buy" with a target price of 59.15, indicating a potential upside, despite recent sideways trading and average market performance. The company specializes in therapies for rare kidney and metabolic diseases, with key products like FILSPARI and Pegtibatinase in development or commercial stages.
Travere Therapeutics, Inc. Revenue Breakdown – NASDAQ:TVTX
Travere Therapeutics, Inc. (NASDAQ: TVTX) generated a total revenue of $490.73 million USD last year. The FILSPARI segment was the primary revenue driver, contributing $322.00 million USD, a significant increase from the previous year. The company's largest market contribution came from the United States, accounting for $410.46 million USD.
Travere Therapeutics Q2 Results: Earnings Date Set for August 4
Travere Therapeutics, Inc. (NASDAQ: TVTX) is set to release its second quarter 2026 financial results on August 4, 2026, after the U.S. markets close. Following the release, a conference call and webcast will be held at 4:30 p.m. ET to discuss the results and provide a business update. The biopharmaceutical company focuses on developing therapies for rare diseases and will make an archived recording of the call available online for 30 days.
Travere Therapeutics to Report Second Quarter 2026 Financial Results
Travere Therapeutics, Inc. announced it will release its second-quarter 2026 financial results on Tuesday, August 4, 2026, after the U.S. financial markets close. The company will also host a conference call and webcast at 4:30 p.m. ET to discuss these results and provide a business update. Access to the webcast and dial-in information will be available on Travere's investor relations website.
TVTX|Travere Therapeutics Inc|Price:55.890|Chg%:-0.790
This article provides a comprehensive stock analysis of Travere Therapeutics Inc (TVTX), highlighting its strong fundamentals, high growth potential, and "fairly valued" status within the Biotechnology & Medical Research industry. Despite trading sideways recently, institutional ownership is very high, and multiple analysts rate the stock as "Buy" with a target price of $59.15. The company specializes in therapies for rare kidney and metabolic diseases, with key products like FILSPARI and Pegtibatinase.
Kuehn Law Encourages Investors of Travere Therapeutics, Inc. to Contact Law Firm
Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether officers and directors of Travere Therapeutics, Inc. (NASDAQ: TVTX) breached their fiduciary duties to shareholders through potential self-dealing. The firm is encouraging long-term TVTX stockholders to contact them, suggesting they may be entitled to damages and corporate governance reforms. The firm operates on a contingency basis, covering all case costs and not charging investor clients, emphasizing the importance of shareholder participation to market integrity.
Travere Therapeutics Inc (TVTX) Technical Analysis: Support, Resistance, Indicators & Moving Averages
This article provides a technical analysis of Travere Therapeutics Inc (TVTX), detailing its price momentum, support and resistance levels, and various technical indicators. The stock currently has a neutral signal based on moving averages and other technical indicators, trading between support at 53.12 and resistance at 60.12. The analysis covers MACD, RSI, KDJ, and moving averages, offering insights for potential range-bound swing trading.
Investigation launched into Travere Therapeutics' officers for possible self-dealing breaches
Kuehn Law, PLLC has initiated an investigation into the officers and directors of Travere Therapeutics for potential breaches of fiduciary duties through self-dealing. This investigation could result in damages for shareholders and foster corporate governance reforms. Long-term shareholders are advised to contact the law firm to safeguard their rights, as concerns about management integrity and shareholder value have been raised.
Travere Therapeutics Inc (TVTX) Institutional Confidence
Travere Therapeutics Inc (TVTX) has an institutional shareholding score of 10.00, placing it first in the Biotechnology & Medical Research industry. The institutional shareholding proportion has increased by 4.06% quarter-over-quarter, with Fidelity Management & Research Company LLC and Fidelity Institutional Asset Management showing significant increases in holdings. James Simons is noted as the largest institutional shareholder.
TVTX|Travere Therapeutics Inc|Price:57.370|Chg%:+0.690
Travere Therapeutics Inc. (TVTX) is a biopharmaceutical company specializing in therapies for rare kidney and metabolic diseases. The article details its key products, including FILSPARI for IgAN and sparsentan for FSGS, and provides essential company information such as executive shareholdings and institutional ownership data. FILSPARI is highlighted as the primary revenue driver, contributing significantly to the company's Q1 2026 earnings.
Travere Therapeutics (TVTX) Gets a Buy from Guggenheim
Guggenheim analyst Vamil Divan reiterated a Buy rating on Travere Therapeutics (TVTX) with a price target of $65.00. This follows similar optimism from TD Cowen, which also maintained a Buy rating with a $60.00 price target. The company recently reported a quarterly revenue of $127.2 million and a GAAP net loss of $37.1 million, showing revenue growth compared to the previous year.
TVTX Stock On Track To Hit Near 20-Year Highs After Filspari Becomes The Only Approved FSGS Treatment
Travere Therapeutics' shares surged after the U.S. FDA approved Filspari for focal segmental glomerulosclerosis (FSGS), a rare kidney disorder, making it the first approved treatment for the condition. Analysts are highly bullish, with Canaccord projecting peak sales of $547 million by 2032 and major banks raising price targets. The approval, despite a narrower label, is expected to drive the stock to near 20-year highs.
Analysts Offer Insights on Healthcare Companies: Travere Therapeutics (TVTX), McKesson (MCK) and Avita Medical (RCEL)
This article provides an overview of analyst ratings for three healthcare companies: Travere Therapeutics (TVTX), McKesson (MCK), and Avita Medical (RCEL). Travere Therapeutics received a Strong Buy consensus with a price target of $58.33, while McKesson also garnered a Strong Buy with an average price target of $937.82. Avita Medical was rated a Moderate Buy with an average price target of $9.00.
Travere Therapeutics, Inc. Stock 12‑Month Price Target Raised to $58.71, Implies 4% Upside
Travere Therapeutics, Inc.'s average 12-month stock price target has been increased to $58.71 from $58.36, indicating a potential upside of approximately 4%. This updated target is based on estimates from 14 analysts, with forecasts ranging from $43 to $70 per share. The consensus rating for TVTX remains at "Buy" among 15 covering analysts.
RTRX5376243 Bond Profile — Key Metrics
This article provides key metrics for the Travere Therapeutics, Inc. (RTRX5376243) bond, including its coupon rate, issue and maturity dates, outstanding amount, and face value. It also details information about Travere Therapeutics, Inc. as a biopharmaceutical company focused on rare diseases.
Exploring High Growth Tech Stocks In The US For July 2026
This article identifies top-performing high-growth tech stocks in the US for July 2026, amidst a market that has seen a 17% increase over the past year. It highlights companies like Travere Therapeutics, Madrigal Pharmaceuticals, and Cloudflare, detailing their operational focus, revenue growth, and future earnings potential. The analysis emphasizes innovation and resilience as key factors for selecting these growth stocks.
RTRX5376243 Bond Risk Profile
This article provides a risk profile for the Travere Therapeutics, Inc. 2.25% 01-MAR-2029 bond (RTRX5376243). It highlights key metrics for credit risk assessment, including security level and issuer rating. The bond is listed on FINRA and indicates that the market is currently closed with no trades.
